Episode 6

full
Published on:

7th Jan 2025

High 5hmC predicts worse OS

In this episode of the HemaSphere podcast, host Charles de Bock discusses the latest research on myelodysplastic syndrome (MDS) with Dr Francesca Tiso and Dr Florentien in 't Hout from Radboud University Medical Center, co-authors of a recent paper published in HemaSphere. The conversation covers the clinical presentation of MDS, treatment options, and the significance of genetic mutations. Delve into their study on the prognostic value of hydroxymethylation levels in patients treated with azacitidine, highlighting the challenges of risk stratification and patient recruitment. They also discuss future research directions and the comparative efficacy of azacitidine and decitabine.

“High 5hmC predicts worse OS” is on our website and all major podcast platforms (Spotify, Apple Podcast, and more) and YouTube.

Listen and enjoy casual, insightful discussions about #hematology research.

You can find the referenced article, in full and open access, here on the HemaSphere website.

Listen for free

Show artwork for HemaSphere Podcast

About the Podcast

HemaSphere Podcast
The HemaSphere Podcast focuses on casual and insightful discussions about select HemaSphere publications and hematology research. Listen to the stories behind the papers.
HemaSphere is the official online, open access journal of the European Hematology Association (EHA). HemaSphere publishes exciting basic, translational, and clinical research in hematology. We are pleased to introduce our new podcast series where our host and guest speakers exchange ideas about select HemaSphere publications. Spend some time with us and enjoy casual and insightful discussions about hematology research. Listen to the stories behind the papers. HemaSphere is always accessible; our full range of open access publications is available at www.hemaspherejournal.com.

About your host

Profile picture for European Hematology Association

European Hematology Association

The European Hematology Association promotes excellence in patient care, research, and education in hematology. We serve medical professionals, researchers, and scientists with an active interest in hematology. We are proud to be the largest European-based organization connecting hematologists worldwide to support career development and research, harmonize hematology education, and advocate for hematologists and hematology